Successful Transactions
A) ARS Labs- (Lithuanian Technology Company)
Food sampling device for freshness measurements.
The technology is the world’s first handheld mobile device that determines the freshness of raw meat, poultry and fish. Once wirelessly connected to your smart phone, via a cloud-based application, the technology measures raw meat gas levels, analyzes results and instantaneously reports the level of its freshness and safety for consumption.
BVC worked diligently with the European manufacturer under contract for their food safety technology device for distribution into China. BVC located a quality distribution Partner and under agreement being finalized, brought the product, under a licensing agreement, into distribution sales for channel markets in China.
B) Metabiomics-
"Metabiomics is an early stage molecular diagnostics company that is developing in-vitro diagnostics, screening tests, and health assays that leverage breakthroughs in next-generation DNA sequencing, computational systems biology, and human microbiome sciences. They are focused on developing a non-invasive microbiome test for the earlier and more accurate detection of colon polyps and colorectal cancer.”
Under a consulting agreement with Metabiomics, BVC located the right strategic China Partner for their technology, brought the Teams together for dialogue which led to a negotiated licensing opportunity for both. Below is a press release on the consummated deal. Through Dr. DeRidder's contacts at SABPA (Sino-American Biomedical and Pharmaceutical Assoc) for which he was a past Vice-chair and a Member of the BOD,, BVC came to know Dr. Shiang Huang, CEO of Kindstar Global Molecular Diagnostics, based in Wuhan, PRC, the China Partner in this deal.
C) US Imaging Firm-
Recently BVC consulting work was successful in raising a major round of China-based financing for a US Medical Device company whose technology is a compact battery powered portable CT scan XRAY imaging unit beneficial for Emerging countries such as PRC. This funding was a major contribution to the Series A round of financing for the US company and included an equity position and a Board of Director seat to the PRC investment firm.
BVC was the Consulting Agent for the US Medical Device firm and traveled to China with the US based CEO. BVC was successful in locating an experienced Cardiovascular Team with manufacturing, product development, regulatory, distribution opportunities, and a well-capitalized firm.
The US Company has also recently been successful in developing a distribution Partnership with Siemens, Germany to augment their product line.
D) CG Oncology, Inc. (Formerly Cold Genesys, Inc.)
BVC located a medical technology, from a large San Diego Pharmaceutical Company, that was not being utilized and spun this technology out under a licensing agreement. After locating the technology, and with much discussion and negotiation, BVC was able to re-incorporate the technology into Cold Genesys, Inc.
BVC was able to fund the initial operations by Chinese-American Angel investors based in the United States and Hong Kong.
As a Founder, Dr. DeRidder was an early Executive of the company and a Board of Director member. With ongoing operations and further need for funding, he was able to source a VC Series A financing from a Hong Kong Venture Firm and other syndicated Taiwanese investors.
About CG Oncology
CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer. Our lead candidate, CG0070, is a selective oncolytic immunotherapy which has completed a Phase 2 trial for the treatment of high-grade NMIBC after BCG failure. Additional indications in MIBC and other solid tumors are being pursued with CG0070 in combination with immune checkpoint modulators. At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide. Learn more at www.cgoncology.com.
CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, on December 10, 2020 they announced the closing of a $47 million Series D preferred stock financing led by new investor Kissei Pharmaceutical Co., Ltd., with participation from existing investors ORI Healthcare Fund, Camford Capital and Perseverance Capital Management.
“We are excited to close our Series D round of funding, which will allow us to advance our late-stage pipeline, as new treatment options are desperately needed for patients with bladder cancer,” said Arthur Kuan, CEO of CG Oncology. “Our clinical progress in oncology is a testament to oncolytic immunotherapy as a novel approach, with our lead candidate CG0070 in both monotherapy and combination therapy studies.
The company has raised a total of $83 MM financing to the present time.